<p>马萨诸塞金融服务公司在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第四季度购买了诺华制药（NYSE:NVS - 免费报告）的新股份。这家机构投资者购买了 19,772 股该公司的股票，价值约为 1,924,000 美元。</p>
<ul>
<li>制药巨头盈利超预期，但股价下跌</li>
</ul>
<p>其他对冲基金和机构投资者最近也买卖了该公司的股票。IHT 财富管理公司在第三季度将其在诺华的持股增加了 44.9%。IHT 财富管理公司目前拥有 3,216 股该公司的股票，价值 369,000 美元，此前在上个季度又购买了 996 股。EP 财富顾问公司在第三季度将其在诺华的持股增加了 15.6%。EP 财富顾问公司目前拥有 13,630 股该公司的股票，价值 1,568,000 美元，此前在此期间又购买了 1,837 股。Orion 投资组合解决方案公司在第三季度将其在诺华的持股增加了 3.4%。Orion 投资组合解决方案公司目前拥有 32,423 股该公司的股票，价值 3,729,000 美元，此前在此期间又收购了 1,079 股。MML 投资者服务公司在第三季度将其在诺华的持股增加了 9.1%。MML 投资者服务公司目前拥有 129,201 股该公司的股票，价值 14,861,000 美元，此前在上个季度又收购了 10,763 股。最后，Cape Cod 五分储蓄银行在第三季度将其在诺华的持股增加了 13.9%。Cape Cod 五分储蓄银行目前拥有 3,346 股该公司的股票，价值 356,000 美元，此前在此期间又购买了 409 股。目前，13.12% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师观点</h2>
<p>一些股票分析师最近对该股票发表了看法。瑞银集团在 2 月 13 日的研究报告中重申了对诺华股票的 “中性” 评级。摩根士丹利在 2 月 12 日的报告中开始覆盖诺华股票，并为该公司设定了 “减持” 评级。StockNews.com 在 2 月 8 日的研究报告中将诺华的评级从 “买入” 上调至 “强力买入”。德意志银行在 2 月 4 日的报告中将诺华的评级从 “持有” 上调至 “买入”。最后，巴克莱在 2 月 3 日的报告中重新发布了对诺华股票的 “减持” 评级。三位股票研究分析师对该股票给予了卖出评级，六位给予了持有评级，一位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 123.38 美元。</p>
<ul>
<li>投资的 20 只最佳医疗保健分红股票</li>
</ul>
<p><strong>阅读我们最新的诺华股票分析</strong></p>
<h2>诺华股票表现</h2>
<p>NYSE:NVS 周三开盘价为 101.80 美元。该公司的流动比率为 1.04，速动比率为 0.84，债务与股本比率为 0.48。该股票的市值为 2080.8 亿美元，市盈率为 17.31，市盈增长比率为 1.70，贝塔值为 0.56。诺华制药的 1 年最低价为 92.35 美元，1 年最高价为 120.92 美元。该股票的 50 日简单移动平均线为 108.98 美元，200 日简单移动平均线为 106.70 美元。</p>
<ul>
<li>Voyager Therapeutics 股票因与诺华达成协议而上涨 30%</li>
</ul>
<p>诺华（NYSE:NVS - 获取免费报告）最近在 1 月 31 日发布了其财报。该公司报告每股收益为 1.98 美元，超出分析师共识预期的 1.80 美元，超出幅度为 0.18 美元。诺华的股本回报率为 37.24%，净利润率为 23.56%。研究分析师预计诺华制药在当前年度的每股收益将达到 8.45 美元。</p>
<h2>诺华宣布分红</h2>
<p>该公司最近还披露了一项分红，该分红于 3 月 12 日支付。3 月 12 日的登记投资者获得了 3.8695 美元的分红。该分红的除息日期为 3 月 12 日。诺华的分红支付比率目前为 42.69%。</p>
<h2>诺华简介</h2>
<p>（免费报告）</p>
<p>诺华制药公司在瑞士及国际上从事医疗产品的研究、开发、生产和营销。该公司为患者和医生提供处方药。它专注于心血管、肾脏和代谢、免疫学、神经科学、肿瘤学、眼科学和血液学等治疗领域。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比诺华更好</li>
<li>NYSE 和 NASDAQ 的区别，以及这对投资者的重要性</li>
<li>免关税股票：3 只具有巨大上涨潜力的超值股票</li>
<li>投资于高市盈率增长股票</li>
<li>高通股价下跌，但相对强弱指数显示其严重超卖</li>
<li>股票中的跳空上涨意味着什么？如何利用跳空</li>
<li>特斯拉的第一大看涨者下调目标价，但仍表示值得买入</li>
</ul>
<p><strong>想看看其他对冲基金持有的 NVS 吗？</strong> 访问 HoldingsChannel.com 获取诺华制药（NYSE:NVS - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在诺华吗？</h2>
<p>在考虑诺华之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而诺华制药并不在名单上。</p>
<p>虽然诺华制药目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

诺华制药

<p>马萨诸塞州金融服务公司在第四季度收购了 19,772 股诺华制药（NYSE:NVS），价值约 190 万美元，具体信息见其向美国证券交易委员会提交的 13F 表格。其他机构投资者也增加了对诺华的持股。分析师对该股票的评级不一，普遍评级为 “持有”，目标价格为 123.38 美元。诺华报告每股收益为 1.98 美元，超出预期，并且最近支付了 3.8695 美元的股息</p>

<p>Massachusetts Financial Services Co. MA bought a new position in shares of Novartis AG (NYSE:NVS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 19,772 shares of the company's stock, valued at approximately $1,924,000.</p>
<div class="lb-trans"><p>马萨诸塞金融服务公司在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第四季度购买了诺华制药（NYSE:NVS - 免费报告）的新股份。这家机构投资者购买了 19,772 股该公司的股票，价值约为 1,924,000 美元。</p>
</div><ul>
<li>Pharma Leader Beats on Earnings, But Shares Fall</li>
</ul>
<div class="lb-trans"><ul>
<li>制药巨头盈利超预期，但股价下跌</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently bought and sold shares of the company. IHT Wealth Management LLC grew its position in Novartis by 44.9% in the 3rd quarter. IHT Wealth Management LLC now owns 3,216 shares of the company's stock valued at $369,000 after buying an additional 996 shares in the last quarter. EP Wealth Advisors LLC raised its holdings in Novartis by 15.6% during the 3rd quarter. EP Wealth Advisors LLC now owns 13,630 shares of the company's stock worth $1,568,000 after buying an additional 1,837 shares during the period. Orion Portfolio Solutions LLC raised its holdings in shares of Novartis by 3.4% during the third quarter. Orion Portfolio Solutions LLC now owns 32,423 shares of the company's stock valued at $3,729,000 after acquiring an additional 1,079 shares during the period. MML Investors Services LLC lifted its position in shares of Novartis by 9.1% in the 3rd quarter. MML Investors Services LLC now owns 129,201 shares of the company's stock valued at $14,861,000 after acquiring an additional 10,763 shares in the last quarter. Finally, Cape Cod Five Cents Savings Bank boosted its position in shares of Novartis by 13.9% in the third quarter. Cape Cod Five Cents Savings Bank now owns 3,346 shares of the company's stock worth $356,000 after buying an additional 409 shares during the period. 13.12% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也买卖了该公司的股票。IHT 财富管理公司在第三季度将其在诺华的持股增加了 44.9%。IHT 财富管理公司目前拥有 3,216 股该公司的股票，价值 369,000 美元，此前在上个季度又购买了 996 股。EP 财富顾问公司在第三季度将其在诺华的持股增加了 15.6%。EP 财富顾问公司目前拥有 13,630 股该公司的股票，价值 1,568,000 美元，此前在此期间又购买了 1,837 股。Orion 投资组合解决方案公司在第三季度将其在诺华的持股增加了 3.4%。Orion 投资组合解决方案公司目前拥有 32,423 股该公司的股票，价值 3,729,000 美元，此前在此期间又收购了 1,079 股。MML 投资者服务公司在第三季度将其在诺华的持股增加了 9.1%。MML 投资者服务公司目前拥有 129,201 股该公司的股票，价值 14,861,000 美元，此前在上个季度又收购了 10,763 股。最后，Cape Cod 五分储蓄银行在第三季度将其在诺华的持股增加了 13.9%。Cape Cod 五分储蓄银行目前拥有 3,346 股该公司的股票，价值 356,000 美元，此前在此期间又购买了 409 股。目前，13.12% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities analysts have recently weighed in on the stock. UBS Group reaffirmed a &#34;neutral&#34; rating on shares of Novartis in a research note on Thursday, February 13th. Morgan Stanley assumed coverage on shares of Novartis in a report on Wednesday, February 12th. They set an &#34;underweight&#34; rating for the company. StockNews.com raised Novartis from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, February 8th. Deutsche Bank Aktiengesellschaft raised shares of Novartis from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Tuesday, February 4th. Finally, Barclays reissued an &#34;underweight&#34; rating on shares of Novartis in a report on Monday, February 3rd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $123.38.</p>
<div class="lb-trans"><p>一些股票分析师最近对该股票发表了看法。瑞银集团在 2 月 13 日的研究报告中重申了对诺华股票的 “中性” 评级。摩根士丹利在 2 月 12 日的报告中开始覆盖诺华股票，并为该公司设定了 “减持” 评级。StockNews.com 在 2 月 8 日的研究报告中将诺华的评级从 “买入” 上调至 “强力买入”。德意志银行在 2 月 4 日的报告中将诺华的评级从 “持有” 上调至 “买入”。最后，巴克莱在 2 月 3 日的报告中重新发布了对诺华股票的 “减持” 评级。三位股票研究分析师对该股票给予了卖出评级，六位给予了持有评级，一位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 123.38 美元。</p>
</div><ul>
<li>20 best healthcare dividend stocks to invest in</li>
</ul>
<div class="lb-trans"><ul>
<li>投资的 20 只最佳医疗保健分红股票</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on Novartis</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的诺华股票分析</strong></p>
</div><h2>Novartis Stock Performance</h2>
<div class="lb-trans"><h2>诺华股票表现</h2>
</div><p>NYSE:NVS opened at $101.80 on Wednesday. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. The stock has a market cap of $208.08 billion, a P/E ratio of 17.31, a PEG ratio of 1.70 and a beta of 0.56. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92. The stock has a 50 day simple moving average of $108.98 and a 200 day simple moving average of $106.70.</p>
<div class="lb-trans"><p>NYSE:NVS 周三开盘价为 101.80 美元。该公司的流动比率为 1.04，速动比率为 0.84，债务与股本比率为 0.48。该股票的市值为 2080.8 亿美元，市盈率为 17.31，市盈增长比率为 1.70，贝塔值为 0.56。诺华制药的 1 年最低价为 92.35 美元，1 年最高价为 120.92 美元。该股票的 50 日简单移动平均线为 108.98 美元，200 日简单移动平均线为 106.70 美元。</p>
</div><ul>
<li>Voyager Therapeutics stock pops 30% on deal with Novartis</li>
</ul>
<div class="lb-trans"><ul>
<li>Voyager Therapeutics 股票因与诺华达成协议而上涨 30%</li>
</ul>
</div><p>Novartis (NYSE:NVS - Get Free Report) last issued its earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Research analysts anticipate that Novartis AG will post 8.45 earnings per share for the current year.</p>
<div class="lb-trans"><p>诺华（NYSE:NVS - 获取免费报告）最近在 1 月 31 日发布了其财报。该公司报告每股收益为 1.98 美元，超出分析师共识预期的 1.80 美元，超出幅度为 0.18 美元。诺华的股本回报率为 37.24%，净利润率为 23.56%。研究分析师预计诺华制药在当前年度的每股收益将达到 8.45 美元。</p>
</div><h2>Novartis Announces Dividend</h2>
<div class="lb-trans"><h2>诺华宣布分红</h2>
</div><p>The business also recently disclosed a dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were paid a $3.8695 dividend. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis's dividend payout ratio is currently 42.69%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项分红，该分红于 3 月 12 日支付。3 月 12 日的登记投资者获得了 3.8695 美元的分红。该分红的除息日期为 3 月 12 日。诺华的分红支付比率目前为 42.69%。</p>
</div><h2>Novartis Profile</h2>
<div class="lb-trans"><h2>诺华简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.</p>
<div class="lb-trans"><p>诺华制药公司在瑞士及国际上从事医疗产品的研究、开发、生产和营销。该公司为患者和医生提供处方药。它专注于心血管、肾脏和代谢、免疫学、神经科学、肿瘤学、眼科学和血液学等治疗领域。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Novartis</li>
<li>How the NYSE and NASDAQ are Different, Why That Matters to Investors</li>
<li>Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Qualcomm Breaks Down But RSI Signals It’s Severely Oversold</li>
<li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li>
<li>Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比诺华更好</li>
<li>NYSE 和 NASDAQ 的区别，以及这对投资者的重要性</li>
<li>免关税股票：3 只具有巨大上涨潜力的超值股票</li>
<li>投资于高市盈率增长股票</li>
<li>高通股价下跌，但相对强弱指数显示其严重超卖</li>
<li>股票中的跳空上涨意味着什么？如何利用跳空</li>
<li>特斯拉的第一大看涨者下调目标价，但仍表示值得买入</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding NVS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 NVS 吗？</strong> 访问 HoldingsChannel.com 获取诺华制药（NYSE:NVS - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novartis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在诺华吗？</h2>
</div><p>Before you consider Novartis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑诺华之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而诺华制药并不在名单上。</p>
</div><p>While Novartis currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺华制药目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

马萨诸塞金融服务公司购买了诺华制药（NYSE:NVS）的 19,772 股股票